JP2002514048A - 短縮型可溶性腫瘍壊死因子i型およびii型レセプター - Google Patents
短縮型可溶性腫瘍壊死因子i型およびii型レセプターInfo
- Publication number
- JP2002514048A JP2002514048A JP50536998A JP50536998A JP2002514048A JP 2002514048 A JP2002514048 A JP 2002514048A JP 50536998 A JP50536998 A JP 50536998A JP 50536998 A JP50536998 A JP 50536998A JP 2002514048 A JP2002514048 A JP 2002514048A
- Authority
- JP
- Japan
- Prior art keywords
- stnfr
- cys
- tumor necrosis
- amino acid
- truncated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0325—Animal model for autoimmune diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/815—Carrier is a synthetic polymer
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.以下の式を有する短縮型sTNFR: R1-[Cys19-Cys103]-R2 ここで、[Cys19-Cys103]とは、sTNFR-Iの残基19〜103を表し、該アミノ酸残基番 号付け図は、比較を容易にするために図1(配列番号2)に提供される; ここで、R1は、Cys19のまたは以下の群から選択される1つまたは複数のアミノ 末端アミノ酸残基の、メチオニル化または非メチオニル化アミン基を表す: そして、ここでR2は、Cys103のまたは以下の群から選択されるカルボキシ末端ア ミノ酸残基の、カルボキシ基を表し: ならびにそれらの改変体および誘導体、ただし、R1がアミノ酸配列VCPQGKYIHPQN NSICのメチオニル化または非メチオニル化アミン基あるいは1〜15残基のそのN 末端短縮型を表す場合、R1-[Cys19-Cys103]-R2は、式R1-[Cys19-Cys103]-FCCSLC L-R3を有する付加改変体ではなく、ここで、R3は図1のアミノ酸残基Asn111-Asn161 のカルボキシル基または図1のAsn111-Asn161のカルボキシ末端短縮型を表す 。 2.sTNFR-I 2.6D/C105、sTNFR-I 2.6D/C106、sTNFR-I 2.6D/N105、sTNFR-I 2 .3D/d8、sTNFR-I 2.3D/d18、およびsTNFR-I 2.3D/d15、またはその改変体もしく は誘導体からなる群より選択される、請求項1に記載の腫瘍壊死結合タンパク質 。 3.以下の式を有する短縮型sTNFR: R4-[Cys32-Cys115]-R5 ここで、[Cys32-Cys115]は、成熟全長40kDa TNFインヒビターの残基Cys32〜Cys1 15 を表し、該アミノ酸残基番号付け図は、比較を容易にするために図8(配列番 号35)に提供される; ここで、R4は、Cys32のまたは以下の群から選択される1つまたは複数のアミノ 末端アミノ酸残基の、メチオニル化または非メチオニル化アミン基を表し: そして、ここでR5は、Cys115のまたは以下の群から選択されるカルボキシ末端ア ミノ酸残基の、カルボキシ基を表し: およびそれらの改変体、ただし、R4がアミノ酸配列TCRLREYYDQTAQMCのメチオニ ル化または非メチオニル化アミン基あるいは1〜15残基のそのN末端短縮型を表 す場合、R4-[Cys32-Cys115]-R5は、式R4-[Cys32-Cys115]-APLRKCR-R6を有する付 加改変体ではなく、ここでR6は図8のアミノ酸残基Pro123-Thr179のカルボキシ ル基または図8のPro123-Thr179のカルボキシ末端短縮型を表す。 4.前記アミノ酸配列がグリコシル化されていない、請求項1〜3のいずれか 一項に記載の腫瘍壊死結合タンパク質。 5.前記アミノ酸配列がグリコシル化される、請求項1〜3のいずれか一項に 記載の腫瘍壊死結合タンパク質。 6.前記タンパク質が、水溶性ポリマーに結合される、請求項1〜5のいずれ か一項に記載の腫瘍壊死結合タンパク質。 7.請求項1〜6のいずれか一項に記載の少なくとも1つの腫瘍壊死結合タン パク質を含む、多価腫瘍壊死結合タンパク質。 8.式R1-X-R2を有する多価腫瘍壊死結合タンパク質: ここで、Xはリンカーを含み、ここで該リンカーは水溶性ボリマーであり;そし て R1およびR2は、該水溶性ポリマーに共有結合される生物学的に活性な分子であり 、ここでR1およびR2の少なくとも1つは、請求項1〜6のいずれか一項に記 載の腫瘍壊死結合タンパク質である。 9.前記水溶性ポリマーがポリエチレングリコールである、請求項8に記載の 多価腫瘍壊死結合タンパク質。 10.前記タンパク質が、sTNFR-I 2.6D/C105dbおよびsTNFR-I 2.6D/C106dbか らなる群より選択される、請求項9に記載の多価腫瘍壊死結合タンパク質。 11.TNF媒介性疾患を処置することにおける使用のための、請求項1〜10 のいずれか一項に記載の腫瘍壊死結合タンパク質。 12.関節炎を処置することにおける使用のための、請求項1〜10のいずれ か一項に記載の腫瘍壊死結合タンパク質。 13.請求項1〜3のいずれか一項に記載の腫瘍壊死結合タンパク質をコード するポリヌクレオチド。 14.以下から選択されるヌクレオチド配列によってコードされる腫瘍壊死因 子結合タンパク質を含む、核酸配列: (a) 図2に示されるcDNA配列; (b) 図3に示されるcDNA配列; (c) 図4に示されるcDNA配列; (d) 図5に示されるcDNA配列; (e) 図6に示されるcDNA配列; (f) 図7に示されるcDNA配列; (g) (a)、(b)、(c)、(d)、(e)、および(f)のコード領域またはその一部におい て縮重である配列; (h) (a)、(b)、(c)、(d)、(e)、(f)、および(g)にハイブリダイズする配列; および (i) (a)、(b)、(c)、(d)、(e)、(f)、(g)、および(h)に相補的である配列、た だし、該核酸は、式R1-[Cys19-Cys103]-FCCSLCL-R3を有するタンパク質をコード しない、ここで[Cys19-Cys103]はsTNFR-Iの残基19〜103を表し、該アミノ酸残基 番号付け図は、比較を容易にするために図1(配列番号2)に提供され;ここで 、R1は、NNSICを含むアミノ酸配列のメチオニル化または非メチオニル化アミン 基を表し、そしてR3は図1のアミノ酸残基Asn111-Asn161のカルボキシル基また は図1のAsn111-Asn161のカルボキシ末端短縮型を表す。 15.図2、3、4、5、6、または7に記載の配列あるいはその一部を有す るポリヌクレオチド。 16.発現制御配列に作動可能に連結された請求項13〜15のいずれか一項 に記載のポリヌクレオチドを含む、ベクター。 17.請求項13〜15のいずれか一項に記載のポリヌクレオチドを含む、原 核生物または真核生物宿主細胞。 18.適切な栄養培地中で請求項17に記載の宿主細胞を増殖する工程、およ び、必要に応じて、該細胞または該栄養培地から該短縮型sTNFRを単離する工程 を包含する、方法。 19.前記宿主細胞がE.coliである、請求項18に記載の腫瘍壊死結合タン パク質の産生方法。 20.前記宿主細胞がチャイニーズハムスター卵巣細胞である、請求項18に 記載の腫瘍壊死因子結合タンパク質の産生方法。 21.以下の工程を包含する方法: (a) 請求項17に記載の原核生物または真核生物宿主細胞を培養する工程; (b) 該宿主細胞による短縮型sTNFRの発現を可能にする条件下で該宿主細胞を 維持する工程;および (c) 必要に応じて、該宿主細胞によって発現される該短縮型sTNFRを単離する 工程。 22.請求項13〜15のいずれか一項に記載の外因性ポリヌクレオチドを含 む原核生物または真核生物宿主細胞の組換え発現産物である、腫瘍壊死結合タン パク質。 23.請求項1〜10のいずれか一項に記載の腫瘍壊死因子結合タンパク質を 、薬学的に受容可能なビヒクルどともに含む、薬学的組成物。 24.請求項18に記載の方法に従って産生される腫瘍壊死因子結合タンパク 質を、薬学的に受容可能なビヒクルとともに含む、薬学的組成物。 25.請求項21に記載の方法に従って産生される腫瘍壊死因子結合タンパク 質を、薬学的に受容可能なビヒクルとともに含む、薬学的組成物。 26.請求項23〜25に記載の薬学的組成物を患者に投与する工程を包含す る、TNF媒介性疾患を処置する方法。 27.前記TNF媒介性疾患が関節炎である、請求項26に記載の方法。 28.薬学的組成物を調製する方法であって、治療的有効量の請求項1〜10 のいずれか一項に記載の腫瘍壊死因子結合タンパク質が、1つ以上の薬学的に受 容可能なビヒクルと混合される、方法。 29.TNF媒介性疾患を処置するための、請求項1〜10のいずれか一項に記 載の腫瘍壊死因子結合タンパク質の使用。 30.関節炎を処置するための、請求項29に記載の腫瘍壊死因子結合タンパ ク質の使用。 31.請求項1〜10のいずれか一項に記載の腫瘍壊死因子結合タンパク質お よび生理学的に受容可能な溶媒を有する第2の容器を含む水性タンパク質処方物 を調製するためのキット。
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2144396P | 1996-07-09 | 1996-07-09 | |
US60/021,443 | 1996-07-09 | ||
US3253496P | 1996-12-06 | 1996-12-06 | |
US60/032,534 | 1996-12-06 | ||
US3773797P | 1997-01-23 | 1997-01-23 | |
US60/037,737 | 1997-01-23 | ||
US3931497P | 1997-02-07 | 1997-02-07 | |
US60/039,314 | 1997-02-07 | ||
US3979297P | 1997-03-04 | 1997-03-04 | |
US60/039,792 | 1997-03-04 | ||
PCT/US1997/012244 WO1998001555A2 (en) | 1996-07-09 | 1997-07-09 | Truncated soluble tumor necrosis factor type-i and type-ii receptors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009197460A Division JP2009280612A (ja) | 1996-07-09 | 2009-08-27 | 短縮型可溶性腫瘍壊死因子i型およびii型レセプター |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002514048A true JP2002514048A (ja) | 2002-05-14 |
JP2002514048A5 JP2002514048A5 (ja) | 2005-04-07 |
Family
ID=27533913
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50536998A Pending JP2002514048A (ja) | 1996-07-09 | 1997-07-09 | 短縮型可溶性腫瘍壊死因子i型およびii型レセプター |
JP2009197460A Pending JP2009280612A (ja) | 1996-07-09 | 2009-08-27 | 短縮型可溶性腫瘍壊死因子i型およびii型レセプター |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009197460A Pending JP2009280612A (ja) | 1996-07-09 | 2009-08-27 | 短縮型可溶性腫瘍壊死因子i型およびii型レセプター |
Country Status (22)
Country | Link |
---|---|
US (2) | US6989147B2 (ja) |
EP (1) | EP0914431B1 (ja) |
JP (2) | JP2002514048A (ja) |
KR (1) | KR20000023695A (ja) |
AT (1) | ATE364695T1 (ja) |
AU (2) | AU3601397A (ja) |
BG (1) | BG64910B1 (ja) |
BR (1) | BR9710350A (ja) |
CA (1) | CA2259156C (ja) |
CZ (1) | CZ296835B6 (ja) |
DE (1) | DE69737814T2 (ja) |
EA (1) | EA003900B1 (ja) |
ES (1) | ES2288304T3 (ja) |
IL (1) | IL127874A0 (ja) |
NO (1) | NO990086L (ja) |
NZ (1) | NZ333647A (ja) |
PL (1) | PL189309B1 (ja) |
SK (1) | SK1599A3 (ja) |
TR (1) | TR199700610A3 (ja) |
TW (1) | TW555765B (ja) |
WO (1) | WO1998001555A2 (ja) |
YU (1) | YU299A (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006512286A (ja) * | 2002-06-20 | 2006-04-13 | アムジエン・インコーポレーテツド | ペグ化可溶性腫瘍壊死因子受容体の改良組成物とその製造方法 |
JP2013507913A (ja) * | 2009-10-19 | 2013-03-07 | ハナル バイオファーマ カンパニーリミテッド | 修飾されたヒト腫瘍壊死因子受容体−1ポリペプチドまたはその断片及びその製造方法 |
JP2014501528A (ja) * | 2010-12-23 | 2014-01-23 | ハノル バイオファーマ カンパニー リミテッド | 修飾されたヒト腫瘍壊死因子受容体−1ポリペプチドまたはその断片及びその製造方法 |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7005413B1 (en) * | 1995-12-22 | 2006-02-28 | Amgen Inc. | Combination therapy for conditions leading to bone loss |
WO1998024477A1 (en) | 1996-12-06 | 1998-06-11 | Amgen Inc. | Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases |
US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
RO128635A2 (ro) | 1997-04-16 | 2013-07-30 | Amgen Inc. | Anticorp sau fragment al acestuia care se leagă la opgbp şi utilizarea acestuia, utilizarea unei forme solubile de odar, şi metodă de identificare a unui compus care descreşte activitatea opgbp |
US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
DE60024636T2 (de) * | 1999-06-21 | 2006-08-17 | Santen Pharmaceutical Co., Ltd | Arzneimittel für die rheumatoide arthritis |
AU2001238076A1 (en) | 2000-02-11 | 2001-08-20 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health | Identification of a novel domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function |
US20030103978A1 (en) | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
US7087224B2 (en) * | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
PT1411970E (pt) | 2000-12-06 | 2007-05-31 | Applied Research Systems | Utilização de sarp-1 para o tratamento e/ou prevenção de escleroderma |
NZ547695A (en) | 2001-06-26 | 2008-09-26 | Amgen Fremont Inc | Antibodies to OPGL |
US7718776B2 (en) | 2002-04-05 | 2010-05-18 | Amgen Inc. | Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors |
WO2004098595A1 (en) * | 2003-05-12 | 2004-11-18 | Altana Pharma Ag | COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST |
WO2005079796A1 (en) * | 2004-02-20 | 2005-09-01 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions based on anticholinergics and pegsunercept |
CA2574881C (en) | 2004-08-04 | 2013-01-08 | Amgen Inc. | Antibodies to dkk-1 |
CA2610839C (en) | 2005-06-14 | 2019-06-25 | Amgen Inc. | Self-buffering protein formulations |
TW200736277A (en) | 2005-11-14 | 2007-10-01 | Amgen Inc | RANKL antibody-PTH/PTHrP chimeric molecules |
US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
WO2009009186A2 (en) * | 2007-04-13 | 2009-01-15 | The Regents Of The University Of California | Receptors useful for gas phase chemical sensing |
RS56743B1 (sr) | 2007-08-21 | 2018-03-30 | Amgen Inc | Humani c-fms antigen vezujući proteini |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
UA101670C2 (ru) | 2008-07-23 | 2013-04-25 | Ханми Сайенс Ко., Лтд. | Полипептидный комплекс, содержащий непептидильный полимер, который имеет три функциональных конца |
ES2652637T3 (es) | 2010-01-15 | 2018-02-05 | Kirin-Amgen, Inc. | Formulación de anticuerpos y regímenes terapéuticos |
KR101273893B1 (ko) | 2010-09-13 | 2013-06-14 | 한올바이오파마주식회사 | 변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드 또는 그의 절편 및 그의 제조방법 |
TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
WO2015087187A1 (en) | 2013-12-10 | 2015-06-18 | Rinat Neuroscience Corp. | Anti-sclerostin antibodies |
EP3250219A4 (en) * | 2015-01-28 | 2018-10-03 | DNX Biotech, LLC | Compositions and methods of using a soluble tnf-alpha receptor modified for increased half-life |
WO2017156058A1 (en) | 2016-03-08 | 2017-09-14 | Janssen Biotech, Inc. | Gitr antibodies, methods, and uses |
KR102413592B1 (ko) | 2016-10-21 | 2022-06-27 | 암젠 인크 | 약학적 제형 및 그의 제조 방법 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0308378A2 (en) * | 1987-09-13 | 1989-03-22 | Yeda Research And Development Company Limited | Tumor necrosis factor (TNF)inhibitory protein and its purification |
JPH03164179A (ja) * | 1989-04-21 | 1991-07-16 | Boehringer Ingelheim Internatl Gmbh | Tnfレセプター、tnf結合たん白質およびこれらをコードするdna |
JPH04299989A (ja) * | 1990-07-12 | 1992-10-23 | Yeda Res & Dev Co Ltd | ヒト腫瘍壊死因子結合蛋白 |
JPH05170661A (ja) * | 1991-05-07 | 1993-07-09 | Yeda Res & Dev Co Ltd | 薬剤組成物 |
WO1995013312A1 (en) * | 1993-11-12 | 1995-05-18 | Shearwater Polymers, Inc. | Water soluble active sulfones of poly(ethylene glycol) |
JPH07145068A (ja) * | 1991-08-07 | 1995-06-06 | Yeda Res & Dev Co Ltd | 溶解型tnf受容体のマルチマー、その製造方法、およびそれを含有する医薬組成物 |
WO1996003141A1 (en) * | 1994-07-22 | 1996-02-08 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions comprising a chimaeric tnf binding protein |
Family Cites Families (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
IN150740B (ja) | 1978-11-24 | 1982-12-04 | Hoffmann La Roche | |
US4760067A (en) | 1979-08-15 | 1988-07-26 | Merck & Co., Inc. | Allylsulfoxide enzyme inhibitors |
EP0040506B1 (en) | 1980-05-21 | 1986-08-20 | Teijin Limited | Reactive polymer and process for the preparation thereof |
US4560649A (en) | 1981-10-15 | 1985-12-24 | Cornell Research Foundation | Assaying for hLH or hCG with immobilized hormone receptors |
JPH0751511B2 (ja) | 1982-03-15 | 1995-06-05 | 味の素株式会社 | インターロイキン2を含有してなる癌治療剤 |
DE3378250D1 (en) | 1982-04-22 | 1988-11-24 | Ici Plc | Continuous release formulations |
US4587046A (en) | 1982-05-18 | 1986-05-06 | The Regents Of The University Of California | Drug-carrier conjugates |
DE3380726D1 (en) | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
US4966888A (en) | 1985-07-08 | 1990-10-30 | Cornell Research Foundation, Inc. | hCG-hLH receptor and hCG-hLH receptor-hCG complex as antigens, antibodies thereto and contraceptive vaccine |
US4522750A (en) | 1984-02-21 | 1985-06-11 | Eli Lilly And Company | Cytotoxic compositions of transferrin coupled to vinca alkaloids |
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
SE470099B (sv) | 1984-05-17 | 1993-11-08 | Jerker Porath | Sulfonaktiverade tioeteradsorbenter för separation av t ex protein |
US4578335A (en) | 1984-05-21 | 1986-03-25 | Immunex Corporation | Interleukin 2 receptor |
US4670563A (en) | 1984-06-20 | 1987-06-02 | Sanofi | Imidazolides as intermediates for the synthesis of cytotoxic conjugates |
US4675285A (en) | 1984-09-19 | 1987-06-23 | Genetics Institute, Inc. | Method for identification and isolation of DNA encoding a desired protein |
SE454885B (sv) | 1984-10-19 | 1988-06-06 | Exploaterings Ab Tbf | Polymerbelagda partiklar med immobiliserade metalljoner pa sin yta jemte forfarande for framstellning derav |
US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
WO1987000056A1 (en) | 1985-06-26 | 1987-01-15 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
JPS62185029A (ja) | 1986-02-07 | 1987-08-13 | Ajinomoto Co Inc | 修飾インタ−ロイキン−2 |
CA1283046C (en) | 1986-05-29 | 1991-04-16 | Nandini Katre | Tumor necrosis factor formulation |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
IN165717B (ja) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
US4931544A (en) | 1986-09-04 | 1990-06-05 | Cetus Corporation | Succinylated interleukin-2 for pharmaceutical compositions |
IL80005A (en) | 1986-09-10 | 1992-11-15 | Yeda Res & Dev | Compositions for modulating the effect of tnf and il-1 |
US4965271A (en) | 1986-12-31 | 1990-10-23 | Hoechst Roussel Pharmaceuticals, Inc. | Method of inhibiting the activity of leukocyte derived cytokines |
US5359032A (en) | 1987-08-26 | 1994-10-25 | Biogen Inc. | Interkeukin-1 inhibitor |
IL90339A (en) | 1989-05-18 | 1996-10-16 | Yeda Res & Dev | Anti-cytotoxic protein and its purification |
US5512544A (en) | 1987-09-13 | 1996-04-30 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising an anticytokine |
US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
US5153265A (en) | 1988-01-20 | 1992-10-06 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
US4847325A (en) | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
GB8806339D0 (en) | 1988-03-17 | 1988-04-13 | Hoffmann La Roche | Monoclonal antibodies |
GB8807803D0 (en) | 1988-03-31 | 1988-05-05 | Glaxo Group Ltd | Biochemical product |
US5256642A (en) | 1988-04-01 | 1993-10-26 | The Johns Hopkins University | Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof |
IL89790A (en) | 1988-04-01 | 2002-05-23 | Johns Hopking University | Sequences of nucleic acids encoding and cells producing CR1 protein and methods for its production and purification |
US5214131A (en) | 1988-05-06 | 1993-05-25 | Sumitomo Pharmaceuticals Company, Limited | Polyethylene glycol derivatives, modified peptides and production thereof |
US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
KR0148009B1 (ko) | 1988-05-27 | 1998-08-01 | 그래고리 비. 아보트 | 인터루킨-1 억제제 |
JPH0240399A (ja) | 1988-07-27 | 1990-02-09 | Takeda Chem Ind Ltd | 線維芽細胞増殖因子ムテインの複合体あるいは組成物 |
US5811261A (en) | 1988-09-12 | 1998-09-22 | Yeda Research And Development Co. Ltd. | Expression of the recombinant tumor necrosis factor binding protein I (TBP-I) |
IL94039A (en) | 1989-08-06 | 2006-09-05 | Yeda Res & Dev | Antibodies to tbp - 1 and their use |
US5359037A (en) | 1988-09-12 | 1994-10-25 | Yeda Research And Development Co. Ltd. | Antibodies to TNF binding protein I |
GB8824592D0 (en) | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Purification process |
US5681566A (en) | 1988-10-24 | 1997-10-28 | 3I Research Exploitation Limited | Antibody conjugates with two or more covalently linked FC regions |
GB8824869D0 (en) | 1988-10-24 | 1988-11-30 | Stevenson G T | Synthetic antibody |
US5162430A (en) | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
WO1990005534A1 (en) | 1988-11-23 | 1990-05-31 | Genentech, Inc. | Polypeptide derivatives |
WO1990006774A1 (en) | 1988-12-22 | 1990-06-28 | Xoma Corporation | Hindered linking agents and methods |
US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
EP0386289A1 (en) | 1989-03-07 | 1990-09-12 | Taniguchi, Tadatsugu, Dr. | Recombinant interleukin-2 receptor |
CA2011450C (en) | 1989-03-07 | 2002-06-04 | Tadatsugu Taniguchi | Recombinant b-chain of the il-2 receptor |
US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
ATE289350T1 (de) * | 1989-04-21 | 2005-03-15 | Amgen Inc | Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas |
US7264944B1 (en) * | 1989-04-21 | 2007-09-04 | Amgen Inc. | TNF receptors, TNF binding proteins and DNAs coding for them |
DE3922089A1 (de) | 1989-05-09 | 1990-12-13 | Basf Ag | Neue proteine und ihre herstellung |
CA2017025C (en) * | 1989-05-18 | 2008-07-22 | David Wallach | Tumor necrosis factor binding protein ii, its purification and antibodies thereto |
IL95031A (en) * | 1989-07-18 | 2007-03-08 | Amgen Inc | A method of producing a recombinant human necrotic factor absorber |
US6143866A (en) * | 1989-07-18 | 2000-11-07 | Amgen, Inc. | Tumor necrosis factor (TNF) inhibitor and method for obtaining the same |
US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
NZ235148A (en) | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
CA2065346C (en) | 1989-09-05 | 2005-03-29 | Craig A. Smith | Tumor necrosis factor-.alpha. and-.beta. receptors |
DK0417563T3 (da) | 1989-09-12 | 2000-11-06 | Hoffmann La Roche | TNF-bindende proteiner |
US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
US5234903A (en) | 1989-11-22 | 1993-08-10 | Enzon, Inc. | Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute |
EP0502956B1 (en) | 1989-11-29 | 1997-04-23 | Amgen Boulder Inc. | Production of recombinant human interleukin-1 inhibitor |
EP0433900B1 (en) * | 1989-12-13 | 1995-09-20 | Yeda Research And Development Company Limited | Expression of the recombinant tumor necrosis factor binding protein I (TBP-I) |
US5136021A (en) | 1990-02-27 | 1992-08-04 | Health Research, Inc. | TNF-inhibitory protein and a method of production |
US5171264A (en) | 1990-02-28 | 1992-12-15 | Massachusetts Institute Of Technology | Immobilized polyethylene oxide star molecules for bioapplications |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
US6458360B1 (en) | 1990-04-25 | 2002-10-01 | The Johns Hopkins University | Soluble complement regulatory molecules |
GB2246569A (en) | 1990-06-15 | 1992-02-05 | Charing Cross Sunley Research | Tumour necrosis factor - alpha binding protein |
WO1992001002A1 (fr) | 1990-07-11 | 1992-01-23 | Teijin Limited | Inhibiteur de l'activite du facteur de la necrose tumorale et son procede de preparation |
GB9015908D0 (en) | 1990-07-19 | 1990-09-05 | Celltech Ltd | Multivalent immunoglobulin |
AU657483B2 (en) | 1990-07-20 | 1995-03-16 | Pharmacia Ab | Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures |
EP0687691B1 (en) | 1990-08-31 | 1998-10-07 | Regents Of The University Of Minnesota | Resin for solid-phase peptide synthesis |
GB9022648D0 (en) | 1990-10-18 | 1990-11-28 | Charing Cross Sunley Research | Polypeptide and its use |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
DK0567566T4 (da) | 1991-01-18 | 2007-10-22 | Amgen Inc | Fremgangsmåder til behandling af tumornekrosefaktor-medierede sygdomme |
JPH06508985A (ja) | 1991-02-27 | 1994-10-13 | クリエイティブ バイオモレキュルズ インコーポレイテッド | 富セリンペプチドリンカー |
ES2199935T3 (es) * | 1991-03-15 | 2004-03-01 | Amgen Inc. | Pegilacion de polipeptidos. |
AU1676992A (en) | 1991-03-18 | 1992-10-21 | Enzon, Inc. | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
JP3340434B2 (ja) | 1991-07-04 | 2002-11-05 | ダコ アクティーゼルスカブ | ジビニルスルホンに由来する成分を含んで成る水溶性ポリマーベース試薬及び抱合体 |
US5569779A (en) | 1991-12-23 | 1996-10-29 | Albemarle Corporation | Polyfunctional michael addition products |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
JPH08502082A (ja) | 1992-07-02 | 1996-03-05 | コラーゲン コーポレイション | 生体適合性ポリマー結合体 |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
NZ256293A (en) | 1992-09-15 | 1997-06-24 | Immunex Corp | Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist |
US6270766B1 (en) | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
EP0622394A1 (en) | 1993-04-30 | 1994-11-02 | S.A. Laboratoires S.M.B. | Reversible modification of sulfur-containing molecules with polyalkylene glycol derivatives and their use |
JPH09509646A (ja) | 1993-07-30 | 1997-09-30 | ケネディー インスティチュート オブ リューマトロジー | 多発性硬化症を治療する方法 |
GB9317618D0 (en) | 1993-08-24 | 1993-10-06 | Royal Free Hosp School Med | Polymer modifications |
DE4441446A1 (de) * | 1994-11-22 | 1996-05-23 | Ulrich Theis | Verfahren zur Übergabe von Wäschestücken und vorzugsweise zur Durchführung des Verfahrens dienende Muldenmangel |
TW313568B (ja) | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
US7429646B1 (en) * | 1995-06-05 | 2008-09-30 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor-like 2 |
US5747639A (en) | 1996-03-06 | 1998-05-05 | Amgen Boulder Inc. | Use of hydrophobic interaction chromatography to purify polyethylene glycols |
-
1997
- 1997-07-08 TW TW086109629A patent/TW555765B/zh not_active IP Right Cessation
- 1997-07-09 EP EP97932603A patent/EP0914431B1/en not_active Expired - Lifetime
- 1997-07-09 SK SK15-99A patent/SK1599A3/sk unknown
- 1997-07-09 CA CA2259156A patent/CA2259156C/en not_active Expired - Fee Related
- 1997-07-09 JP JP50536998A patent/JP2002514048A/ja active Pending
- 1997-07-09 EA EA199900095A patent/EA003900B1/ru not_active IP Right Cessation
- 1997-07-09 CZ CZ0000499A patent/CZ296835B6/cs not_active IP Right Cessation
- 1997-07-09 DE DE69737814T patent/DE69737814T2/de not_active Expired - Lifetime
- 1997-07-09 WO PCT/US1997/012244 patent/WO1998001555A2/en active IP Right Grant
- 1997-07-09 AU AU36013/97A patent/AU3601397A/en not_active Abandoned
- 1997-07-09 AT AT97932603T patent/ATE364695T1/de not_active IP Right Cessation
- 1997-07-09 NZ NZ333647A patent/NZ333647A/xx unknown
- 1997-07-09 IL IL12787497A patent/IL127874A0/xx unknown
- 1997-07-09 ES ES97932603T patent/ES2288304T3/es not_active Expired - Lifetime
- 1997-07-09 TR TR97/00610A patent/TR199700610A3/tr unknown
- 1997-07-09 BR BR9710350A patent/BR9710350A/pt not_active IP Right Cessation
-
1999
- 1999-01-05 PL PL97331240A patent/PL189309B1/pl not_active IP Right Cessation
- 1999-01-06 YU YU299A patent/YU299A/sr unknown
- 1999-01-08 NO NO990086A patent/NO990086L/no not_active Application Discontinuation
- 1999-01-09 KR KR1019997000152A patent/KR20000023695A/ko not_active Application Discontinuation
- 1999-01-18 BG BG103091A patent/BG64910B1/bg unknown
-
2001
- 2001-01-08 AU AU11121/01A patent/AU774307B2/en not_active Ceased
- 2001-06-15 US US09/882,735 patent/US6989147B2/en not_active Expired - Lifetime
-
2005
- 2005-05-10 US US11/126,126 patent/US7732587B2/en not_active Expired - Fee Related
-
2009
- 2009-08-27 JP JP2009197460A patent/JP2009280612A/ja active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0308378A2 (en) * | 1987-09-13 | 1989-03-22 | Yeda Research And Development Company Limited | Tumor necrosis factor (TNF)inhibitory protein and its purification |
JPH03164179A (ja) * | 1989-04-21 | 1991-07-16 | Boehringer Ingelheim Internatl Gmbh | Tnfレセプター、tnf結合たん白質およびこれらをコードするdna |
JPH04299989A (ja) * | 1990-07-12 | 1992-10-23 | Yeda Res & Dev Co Ltd | ヒト腫瘍壊死因子結合蛋白 |
JPH05170661A (ja) * | 1991-05-07 | 1993-07-09 | Yeda Res & Dev Co Ltd | 薬剤組成物 |
JPH07145068A (ja) * | 1991-08-07 | 1995-06-06 | Yeda Res & Dev Co Ltd | 溶解型tnf受容体のマルチマー、その製造方法、およびそれを含有する医薬組成物 |
WO1995013312A1 (en) * | 1993-11-12 | 1995-05-18 | Shearwater Polymers, Inc. | Water soluble active sulfones of poly(ethylene glycol) |
WO1996003141A1 (en) * | 1994-07-22 | 1996-02-08 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions comprising a chimaeric tnf binding protein |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006512286A (ja) * | 2002-06-20 | 2006-04-13 | アムジエン・インコーポレーテツド | ペグ化可溶性腫瘍壊死因子受容体の改良組成物とその製造方法 |
JP2011137005A (ja) * | 2002-06-20 | 2011-07-14 | Amgen | ペグ化可溶性腫瘍壊死因子受容体の改良組成物とその製造方法 |
JP4847011B2 (ja) * | 2002-06-20 | 2011-12-28 | アムジエン・インコーポレーテツド | ペグ化可溶性腫瘍壊死因子受容体の改良組成物とその製造方法 |
JP2013507913A (ja) * | 2009-10-19 | 2013-03-07 | ハナル バイオファーマ カンパニーリミテッド | 修飾されたヒト腫瘍壊死因子受容体−1ポリペプチドまたはその断片及びその製造方法 |
JP2014501528A (ja) * | 2010-12-23 | 2014-01-23 | ハノル バイオファーマ カンパニー リミテッド | 修飾されたヒト腫瘍壊死因子受容体−1ポリペプチドまたはその断片及びその製造方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002514048A (ja) | 短縮型可溶性腫瘍壊死因子i型およびii型レセプター | |
EP0942740B1 (en) | Combination therapy using a tnf binding protein for treating tnf-mediated diseases | |
JP4344404B2 (ja) | インターロイキン―1インヒビターおよび制御放出ポリマーを含む組成物 | |
JP4771563B2 (ja) | Il−1媒介疾患を処置するためにil−1インヒビターを使用する組合せ療法 | |
US6294170B1 (en) | Composition and method for treating inflammatory diseases | |
KR19990082399A (ko) | 인터루킨-1 저해제 및 조절 방출 중합체를 함유하는 조성물 | |
AU771793B2 (en) | Combination therapy using a TNF binding protein for treating TNF-mediated diseases | |
EP1352656A2 (en) | Combination therapy using a TNF binding protein for treating TNF-mediated diseases | |
MXPA99005224A (en) | Combination therapy using a tnf binding protein for treating tnf-mediated diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040630 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040630 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070116 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070418 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070515 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070615 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070709 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070717 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070827 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090428 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090827 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20091022 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20091105 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110209 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110216 |